Restless Legs Syndrome Epidemiology and Management

Restless Legs Syndrome (RLS) is a sensorimotor disorder characterised by an irresistible urge to move the legs, typically accompanied by uncomfortable sensations that worsen during periods of rest and in the evening. Globally, prevalence estimates range from 5% to 10% in adults, with higher rates observed in older populations and in women. Epidemiological data indicate considerable geographic variation, influenced by genetic predisposition, iron status and comorbid conditions such as renal insufficiency, diabetes and peripheral neuropathy. Delayed diagnosis is common, owing to symptom overlap with other movement disorders and inconsistent application of diagnostic criteria.

Management strategies encompass both pharmacological and non-pharmacological approaches. First-line pharmacotherapy includes dopaminergic agents and α2δ ligands, which alleviate symptoms by modulating central neurotransmission. Iron supplementation, administered orally or intravenously, is indicated in patients with low ferritin levels. Long-term dopaminergic therapy may lead to augmentation, a phenomenon in which symptom onset advances or intensifies, necessitating dose adjustment or drug rotation. Complementary measures such as structured exercise programmes, pneumatic compression devices, behavioural sleep interventions and relaxation techniques can improve sleep quality and reduce symptom burden. Emerging digital health tools for symptom tracking and risk prediction models may further personalise management and bridge barriers to care in underserved regions.

Research from Nature Portfolio

Recent studies have expanded the genetic understanding of RLS, revealing multiple novel risk loci and enhancing predictive accuracy. Genome-wide meta-analyses in over one million individuals have increased the number of susceptibility loci substantially, highlighting targets such as glutamate receptor subunits and other druggable genes. Sex-specific analyses demonstrate largely overlapping genetic architecture in men and women. Mendelian randomisation suggests causal links between RLS and cardiometabolic traits, including diabetes, while machine learning models that integrate genetic and clinical data achieve high predictive performance, with area under the receiver operating curve exceeding 0.80. These insights inform new avenues for therapeutic development and risk stratification.

Restless Legs Syndrome Epidemiology and Management publication trend

The graph below shows the total number of articles in restless legs syndrome epidemiology and management across all publications each year (not limited to Nature Index journals).

Technical terms

Genome-wide association study (GWAS): A systematic approach that scans the entire genome to identify genetic variants associated with a particular disease.

Dopaminergic agents: Medications that stimulate or mimic dopamine receptor activity to relieve RLS symptoms.

α2δ ligands: Drugs that bind the alpha-2-delta subunit of voltage-gated calcium channels, reducing neurotransmitter release involved in sensory disturbances.

Augmentation: A paradoxical worsening of RLS symptoms during long-term treatment, often manifesting as earlier onset or increased severity.

Periodic limb movements: Involuntary, repetitive limb jerks during sleep, frequently coexisting with RLS and contributing to sleep fragmentation.

References

1. Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction. Nature Genetics (2024).
2. Restless leg syndrome and risk of all-cause dementia: a nationwide retrospective cohort study. Alzheimer's Research & Therapy (2023).
3. Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study. BMC Nephrology (2013).
4. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders (2017).
5. Restless Legs Syndrome: From Pathophysiology to Clinical Diagnosis and Management. Frontiers in Aging Neuroscience (2017).